Last reviewed · How we verify
stealth liposomal doxorubicin
Stealth liposomal doxorubicin is a formulation of doxorubicin that uses liposomes to improve its delivery and reduce its cardiotoxicity.
Stealth liposomal doxorubicin is a formulation of doxorubicin that uses liposomes to improve its delivery and reduce its cardiotoxicity. Used for Relapsed or refractory ovarian cancer, Relapsed or refractory multiple myeloma.
At a glance
| Generic name | stealth liposomal doxorubicin |
|---|---|
| Sponsor | National Cancer Institute, Naples |
| Drug class | anthracycline |
| Target | topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The liposomes help to prolong the circulation time of doxorubicin in the bloodstream, allowing it to accumulate in tumors and reduce its exposure to healthy tissues. This can lead to improved efficacy and reduced side effects compared to traditional doxorubicin formulations.
Approved indications
- Relapsed or refractory ovarian cancer
- Relapsed or refractory multiple myeloma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Stomatitis
- Hair loss
- Cardiotoxicity
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (PHASE1)
- Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas (PHASE1)
- A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer (PHASE1)
- Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer (PHASE2)
- A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (PHASE2)
- Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- stealth liposomal doxorubicin CI brief — competitive landscape report
- stealth liposomal doxorubicin updates RSS · CI watch RSS
- National Cancer Institute, Naples portfolio CI